Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Renal Cell Carcinoma: early-phase trial registry
7 of 13 indexed Advanced Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Advanced Renal Cell Carcinoma: 13 US clinical trials tracked, 7 recruiting.
Advanced Renal Cell Carcinoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition advanced-renal-cell-carcinoma
OPEN 7 | RECR 54% | LATE 0 | EARLY 12 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Autoimmune Diseases (54% recruiting · 26 trials)
Advanced Renal Cell Carcinoma lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Renal Cell Carcinoma is recruiting above its size-band peers.
7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Renal Cell Carcinoma research.
M.D. Anderson Cancer Center accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Renal Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Advanced Renal Cell Carcinoma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT07227415
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT05967533
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Karie Runcie
NCT06863311
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT06265285
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
M.D. Anderson Cancer Center
NCT05703854
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT05092373
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel
NCT06399419
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
University of California, San Francisco
NCT02735252
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071223
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune
NCT04522323
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
NCT05122546
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
NCT05239533
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Michael B. Atkins, MD
NCT03117309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Renal Cell Carcinoma page
13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Advanced Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Advanced Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Renal Cell Carcinoma condition card totals 13 registered trials; most-linked intervention Cabozantinib S-malate; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.